HIV prevention for transgender and gender diverse people
Part of Infections clinical trials.
This study tests an experimental medicine (alimatravir, also called MK-8527) as a way to prevent HIV infection. The trial is designed specifically for transgender and gender diverse people who are on gender-affirming hormone therapy and have a low risk of HIV exposure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be HIV-negative (not living with HIV) at the time of the study.
- You identify as transgender or gender diverse (your gender identity differs from the sex you were assigned at birth).
- You are on a stable dose of gender-affirming hormone therapy (like estrogen or testosterone) and plan to keep it the same through the study.
- You have a low likelihood of being exposed to HIV (for example, using condoms or PrEP consistently, or having a partner who is HIV-negative).
- You must not have an active hepatitis B infection.
- You must not have had any cancer (other than certain treated skin or early-stage anal/cervical cancers) in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
This study tests how a long-acting injectable HIV prevention drug (cabotegravir) works in people who also use hormone therapy (like birth control or gender-affirming hormones). The goal is to see if the hormones affect how well the drug prevents HIV. If you are HIV-negative, use hormones, and meet other health criteria, you may be able to join.
This study helps transgender women who are not regularly using PrEP (a daily pill to prevent HIV) get access to HIV prevention services. It uses a smartphone to take pictures and connect with support.
This trial tests a combination of an HIV vaccine and a new antibody treatment (GS-2872) to see if it can help control HIV without daily pills. It is for people with well-controlled HIV who are looking for ways to reduce their dependence on antiretroviral therapy.
This trial tests a new medication called MK-8527 to see if it can prevent HIV-1 infection in women who are at risk. If you are a cisgender woman, HIV-negative, and sexually active, this study could be an option for you.
This trial tests an adapted approach to improve HIV prevention and care for transgender women in Ho Chi Minh City. It aims to help participants stay healthy and access services.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.